Key Takeaways
- Volume growth hit 11% despite self-inflicted and external drags: Management says 15% was achievable absent semiconductor shortages stalling printing machines and IML label supply failures, which together cost ~3–4% of sales.
- Paints slowed sharply to 4% growth, pulling its value share from 59% to 53.8% YoY, while Lubes grew 26% and Food & FMCG grew to 24.1% of revenue, reshaping the mix.
- EBITDA was dampened by ~₹1–1.5 Cr in one-off costs from buying expensive outside labels and a 12–15% power cost hike across all three operating states, with full pass-through taking up to a year.
- The dispenser pump business is a clear disappointment: Wipro volumes collapsed from a planned 0.2–0.3 Cr pumps/month to 2–4 lakhs, and management is now in capital-recovery mode rather than growth mode.
- What to watch next quarter: Whether the two new label printing machines commissioned by December actually eliminate outside label purchases and restore the ~₹3–4 Cr annual OPM benefit, and whether QR code trials with Valvoline/Castrol convert to commercial orders.
Volume Growth & the Quarter’s Miss
- Demand was there, execution wasn’t: Management stated the quarter could have delivered 15% volume growth, but semiconductor shortages meant automated machine spares took 1–1.5 months instead of the usual 1 week–10 days, idling printing lines and robotics.
- IML label bottleneck: The inability to print enough IML labels in-house forced the company to buy from outside, but few IML label manufacturers exist and they could not deliver quality or quantity in time, costing ~3–4% of sales.
- Seasonal weakness compounded the hit: Q2 and Q3 are structurally weaker quarters because monsoons reduce painting activity and consumption of frozen/dairy foods; lube volumes dropped from >2,600 tonnes in Q1 to <2,000 tonnes in Q2, which management called a normal seasonal pattern.
- PAT grew 10.5% YoY, broadly tracking volume growth rather than revenue growth, as cost headwinds absorbed the top-line benefit.
Lakshmana Rao: "In fact the demand is still better. We could have easily posted a 15% volume growth had we got the spares and support in time, but unfortunately worldwide there is a shortage of semiconductors and electronic parts, spare parts or maintenance parts and supply of printing machines not come in as expected by us."
Segment Mix Shift
| Segment | Value Share (Q2 FY22) | Value Share (Q2 FY23) | YoY Growth | Commentary |
|---|---|---|---|---|
| Paints | 59.0% | 53.8% | ▲ 4% | Extended monsoon hurt offtake; Asian Paints increased credit terms. |
| Lubes | 19.3% | 22.0% | ▲ 26% | Driven by IML conversion wins with Valvoline, Benzol and other private majors; DEF product growth continued. |
| Food & FMCG | 21.4% | 24.1% | ▲ strong | Gaining share; new Daman and Panipat plants being built primarily for this segment. |
- Lubes outperformed its industry 6x: The lube industry grew only 5–6% while Mold-Tek grew 30% in lubes, because private-sector majors gave long-term agreements shifting more products into IML, and DEF product growth continued.
- IML share rose across the board: IML and labeled containers volume share improved from 58.7% to 62.5% YoY, and value share from 62.3% to 66.6%, reflecting the strategic push toward higher-value packaging.
Cost Headwinds & Margin Pressure
- Power costs rose 12–15% across Telangana, Andhra Pradesh and Daman; power is ~7% of manufacturing cost, so the overall cost base rose ~1%. Recovery from clients takes 3–4 months for 70–80% approval, with the remaining 20–30% potentially taking 6 months to a year.
- Outside label purchases hit both cost and quality: Buying IML labels externally raised costs and increased rejections, adding ~₹1–1.5 Cr to expenses in the quarter. The fix, doubling in-house printing capacity by December, is expected to save ~₹3–4 Cr per annum at the OPM level from January onward.
- Transport costs rose on diesel price increases, adding a third layer of margin pressure alongside power and label costs.
- Raw materials have stabilized: Prices have held at ₹105–110 (±₹3–4) for 4–5 months after spiking to ₹140 in Feb–Mar last FY, removing one source of volatility.
Capacity Build-Out & Plant Pipeline
- Label printing capacity more than doubling: Three machines currently; two more being added by end-November/mid-December; a sixth, higher-versatility machine planned by January-end if trials succeed, covering needs for the next 3–4 years.
- Panipat plant (ABG/Grasim): Letter of intent received for paint packaging; commercials expected October 2023 with numbers stabilizing in FY2024-25. Food & FMCG manufacturing also planned there to serve Northern clients and provide a Plan B if paint volumes underwhelm.
- Daman plant: Land acquired for food and FMCG (not paints); construction to start May–June 2023, completion within six months thereafter, targeting West-based food and FMCG majors.
- Sultanpur: Adding food & FMCG capacities alongside ongoing IBM expansion; pharmaceutical unit also coming up.
- Total capacity addition: ~11,500 tonnes this year across thin-wall, bulk packs and IBM; another ~11,000–12,000 tonnes next year; ~24,000–25,000 tonnes over two financial years.
- Asian Paints expansion: Another 2,000 tonnes of bulk pack production to be added in Mysuru and Vizag per Asian Paints’ projections; further participation possible in 2–3 years as Asian Paints executes its own expansion plans.
Lakshmana Rao: "See as I told you we are very careful in our assessment for setting up any new plants and we are also have a plan B like producing our food and FMCG products in that region... we are prudent in our investments and we will have other products also other than just paints to make sure that our investments reap good benefits."
Pharma & IBM: The Next Margin Driver
- Pharma IBM timeline has slipped: Commercial trials now expected April–May 2023 (delayed from Q1 due to late machine arrivals); client approval takes 3–6 months each, so commercial invoicing likely only from mid-FY24, with meaningful numbers from FY2024-25.
- OTC product (IBM) closer to launch: Expected January–February 2023, order value ~₹7–8 Cr per annum, adding numbers in FY24.
- Dairy on pharma machines: Clients have asked for development and orders are confirmed; these will run on the same pharmaceutical machines to avoid idle time, contributing from next financial year.
- EBITDA trajectory tied to pharma ramp: Management expects EBITDA to move toward 45% as pharma contributes small amounts in FY24 and decent amounts in FY25, with the aspiration to reach that region in a couple of years.
- Competitive positioning: Management does not expect a price war to enter pharma packaging, but says even if competitive pricing is needed, productivity management can preserve similar EBITDA margins to incumbents.
- Hyderabad Pharma Park: Huge plants coming up by 2024–2025 with land allocations starting October 2022; Mold-Tek sees itself well-positioned with established contacts and reputation.
Lakshmana Rao: "With the addition of Pharma in the year 2023-2024 to a very small extent but from 2024 to 2025 in a decent manner we will be in a position to ramp up the EBITDA numbers towards 45 levels so as I indicated last quarter also in a couple of years we can look at EBITDA in the region of 45."
Dispenser Pumps: Acknowledged Disappointment
- Wipro volumes collapsed: From a planned 0.2–0.3 Cr pumps/month, Wipro’s requirement dropped to 2–4 lakhs/month; total volumes from all clients remain below 0.1 Cr/month against annual capacity of 0.5–0.6 Cr.
- Strategy shifted to capital recovery: Management is holding for a couple of pump varieties already invested in and trying to break even and recover investment costs; no major growth outlook indicated.
- Machines are fungible, molds are not: The ~₹3 Cr investment in molds and assembly machines remains partially utilized and will stay that way for the next few quarters, though the base machines have been redeployed.
- Further delay flagged: Indication from Wipro of additional delay; major volumes now expected December/January but not crossing ₹0.1–0.15 Cr/month.
Lakshmana Rao: "Yes I agree and admit that the dispenser pumps our business is not at par with what we anticipated... So having identified that this could be an area of not so great performance in future we are holding for a couple of varieties of pumps what we invested on and trying to break even and recover our costs of the investment."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY23 volume growth | Very close to 20% (first time in company history exceeding 15%) | FY23, barring drastic economic events |
| FY24 volume growth | 15% definitely possible; very close to 20% if Pharma picks up a little, Panipat starts some production, and Daman adds Asian clients | FY24 |
| In-house label printing capacity | Two new machines by end-Nov/mid-Dec 2022; sixth machine by Jan-end if trials succeed; stops outside label purchases | By January 2023 |
| OPM benefit from in-house labels | ~₹3–4 Cr per annum savings, improving margins | From January 2023 onward |
| OTC product (IBM) commercial start | Order value ~₹7–8 Cr per annum | January–February 2023 |
| Pharma IBM commercial trials | Trials begin; client approvals take 3–6 months each | April–May 2023 |
| Pharma commercial invoicing | Meaningful numbers | From mid-FY24; material only in FY2024-25 |
| Panipat plant commercials | Plant operational, numbers stabilize | October 2023; FY2024-25 |
| Daman plant (food & FMCG) | Construction start, completion within six months | May–June 2023 start |
| EBITDA margin | Ramp toward 45 levels | In a couple of years (FY25–FY26 timeframe) |
| Next 3 years volume growth | 15–20% range | FY23–FY25 |
| Power cost pass-through | 70–80% of clients approve in 3–4 months; remaining 20–30% in 6 months to 1 year | Ongoing |
| QR code commercialization | Hoping one player (Valvoline/Castrol) starts | This quarter or by end of calendar year 2022 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Volume growth | 11% YoY |
| Revenue growth (rupee terms) | 14.4% YoY |
| PAT growth | 10.5% YoY |
| EBITDA | ~₹41 cr, would have been 42–43 cr without label and power cost impacts |
| IML and labeled containers volume share | 62.5%, up from 58.7% in Q2 FY22 |
| IML and labeled containers value share | 66.6%, up from 62.3% in Q2 FY22 |
| Paints segment value share | 53.8%, down from 59% in Q2 FY22 |
| Lubes segment value share | 22%, up from 19.3% in Q2 FY22 |
| Food and FMCG segment value share | 24.1%, up from 21.4% in Q2 FY22 |
| Paints volume | 4,850 tonnes, grew 4% YoY |
| Lubes volume | ~2,000 tonnes, grew 26% YoY; sequential decline from over 2,600 tonnes in Q1 FY23 |
| Food and FMCG volume | 1,520 tonnes |
| Lubes revenue | ₹40 cr, down ~25% sequentially from ₹55 cr in Q1 FY23 |
| H1 FY23 sales | ~₹400 cr |
| Debtors | ₹159 cr in H1 FY23, up from ₹143 cr in FY22 and ~₹90 cr in FY21 |
| Raw material price | ₹105–110, stabilizing after hitting ₹140 in Feb–Mar FY22 |
| FY23 volume growth target | 15–20%, confident of reaching close to 20% |
| FY24 volume growth outlook | 15% minimum, could approach 20% if Pharma and Panipat contribute |
| Total capacity addition planned (FY23–FY24) | 24,000–25,000 tonnes |
| ABG Panipat plant expected volume (year two) | 1,500–2,000 tonnes, commercials from Oct 2023 |
| Dispenser pump capacity | 0.5–0.6 cr pumps per annum; current volumes below 0.1 cr per month |
| Lost sales due to IML label shortage | 3–4% of sales in Q2 |
| Additional cost from outside label procurement | ₹1–1.5 cr |
| In-house label making savings expected | ₹3–4 cr per annum at OPM level once capacities created by Jan |
| Power cost increase | 12–15% across Telangana, Andhra, Daman; contributed ~1% to overall cost increase |
| Internal accruals (net of dividend) | ₹90–100 cr |
| Debt-equity ratio | less than 0.1, including working capital debt |
| Annual investment capacity | ₹100–120 cr from internal accruals and debt |